18F-FDG PET/CT can predict development of thyroiditis due to immunotherapy for lung cancer

Naghmehossadat Eshghi, Linda L Garland, Emily Nia, Robert Betancourt, Elizabeth A Krupinski, Phillip H Kuo

Research output: Contribution to journalArticle

Abstract

Our primary purpose was to determine whether increased 18FFDG uptake in the thyroid gland predicts development of thyroiditis with subsequent hypothyroidism in patients undergoing immunotherapy with nivolumab for lung cancer. Secondarily, we determined whether 18F-FDG uptake in the thyroid gland correlates with number of administered cycles of nivolumab. Methods: Retrospective chart review over 2 y found 18 lung cancer patients treated with nivolumab who underwent 18FFDG PET/CT before and during therapy. SUVmean, SUVmax, and total lesion glycolysis of the thyroid gland were measured. SUVs were also measured for the pituitary gland, liver, and spleen. Patients underwent monthly thyroid testing. PET/CT parameters were analyzed by unpaired t testing for differences between 2 groups (patients who developed hypothyroidism and those who did not). Correlation between development of thyroiditis and number of cycles of nivolumab was also tested. Results: Six of 18 patients developed hypothyroidism. The t test comparing the 2 groups demonstrated significant differences in SUVmean (P 5 0.04), SUVmax (P 5 0.04), and total lesion glycolysis (P 5 0.02) of the thyroid gland. Two of 4 patients who developed thyroiditis and had increased 18F-FDG uptake in the thyroid gland had a normal TSH level at the time of follow-up 18F-FDG PET/CT. Patients who developed thyroiditis with subsequent hypothyroidism stayed longer on therapy (10.6 cycles) than patients without thyroiditis (7.6 cycles), but the trend was not statistically significant. No significant difference in PET/CT parameters was observed for pituitary gland, liver, or spleen. Conclusion: 18F-FDG PET/CT can predict the development of thyroiditis with subsequent hypothyroidism before laboratory testing. Further study is required to confirm the positive trend between thyroiditis and duration of therapy.

LanguageEnglish (US)
Pages260-264
Number of pages5
JournalJournal of Nuclear Medicine Technology
Volume46
Issue number3
StatePublished - Sep 1 2018

Fingerprint

Thyroiditis
Fluorodeoxyglucose F18
Immunotherapy
Lung Neoplasms
Hypothyroidism
Thyroid Gland
Glycolysis
Pituitary Gland
Spleen
Liver
Therapeutics
nivolumab

Keywords

  • FFDG-PET/CT
  • Immunotherapy
  • Lung
  • Lung cancer
  • Molecular imaging
  • Oncology
  • PET/CT
  • Thyroiditis

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging

Cite this

18F-FDG PET/CT can predict development of thyroiditis due to immunotherapy for lung cancer. / Eshghi, Naghmehossadat; Garland, Linda L; Nia, Emily; Betancourt, Robert; Krupinski, Elizabeth A; Kuo, Phillip H.

In: Journal of Nuclear Medicine Technology, Vol. 46, No. 3, 01.09.2018, p. 260-264.

Research output: Contribution to journalArticle

@article{5089906ef6a54e07805a90bf567d57a8,
title = "18F-FDG PET/CT can predict development of thyroiditis due to immunotherapy for lung cancer",
abstract = "Our primary purpose was to determine whether increased 18FFDG uptake in the thyroid gland predicts development of thyroiditis with subsequent hypothyroidism in patients undergoing immunotherapy with nivolumab for lung cancer. Secondarily, we determined whether 18F-FDG uptake in the thyroid gland correlates with number of administered cycles of nivolumab. Methods: Retrospective chart review over 2 y found 18 lung cancer patients treated with nivolumab who underwent 18FFDG PET/CT before and during therapy. SUVmean, SUVmax, and total lesion glycolysis of the thyroid gland were measured. SUVs were also measured for the pituitary gland, liver, and spleen. Patients underwent monthly thyroid testing. PET/CT parameters were analyzed by unpaired t testing for differences between 2 groups (patients who developed hypothyroidism and those who did not). Correlation between development of thyroiditis and number of cycles of nivolumab was also tested. Results: Six of 18 patients developed hypothyroidism. The t test comparing the 2 groups demonstrated significant differences in SUVmean (P 5 0.04), SUVmax (P 5 0.04), and total lesion glycolysis (P 5 0.02) of the thyroid gland. Two of 4 patients who developed thyroiditis and had increased 18F-FDG uptake in the thyroid gland had a normal TSH level at the time of follow-up 18F-FDG PET/CT. Patients who developed thyroiditis with subsequent hypothyroidism stayed longer on therapy (10.6 cycles) than patients without thyroiditis (7.6 cycles), but the trend was not statistically significant. No significant difference in PET/CT parameters was observed for pituitary gland, liver, or spleen. Conclusion: 18F-FDG PET/CT can predict the development of thyroiditis with subsequent hypothyroidism before laboratory testing. Further study is required to confirm the positive trend between thyroiditis and duration of therapy.",
keywords = "FFDG-PET/CT, Immunotherapy, Lung, Lung cancer, Molecular imaging, Oncology, PET/CT, Thyroiditis",
author = "Naghmehossadat Eshghi and Garland, {Linda L} and Emily Nia and Robert Betancourt and Krupinski, {Elizabeth A} and Kuo, {Phillip H}",
year = "2018",
month = "9",
day = "1",
language = "English (US)",
volume = "46",
pages = "260--264",
journal = "Journal of Nuclear Medicine Technology",
issn = "0091-4916",
publisher = "Society of Nuclear Medicine Inc.",
number = "3",

}

TY - JOUR

T1 - 18F-FDG PET/CT can predict development of thyroiditis due to immunotherapy for lung cancer

AU - Eshghi, Naghmehossadat

AU - Garland, Linda L

AU - Nia, Emily

AU - Betancourt, Robert

AU - Krupinski, Elizabeth A

AU - Kuo, Phillip H

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Our primary purpose was to determine whether increased 18FFDG uptake in the thyroid gland predicts development of thyroiditis with subsequent hypothyroidism in patients undergoing immunotherapy with nivolumab for lung cancer. Secondarily, we determined whether 18F-FDG uptake in the thyroid gland correlates with number of administered cycles of nivolumab. Methods: Retrospective chart review over 2 y found 18 lung cancer patients treated with nivolumab who underwent 18FFDG PET/CT before and during therapy. SUVmean, SUVmax, and total lesion glycolysis of the thyroid gland were measured. SUVs were also measured for the pituitary gland, liver, and spleen. Patients underwent monthly thyroid testing. PET/CT parameters were analyzed by unpaired t testing for differences between 2 groups (patients who developed hypothyroidism and those who did not). Correlation between development of thyroiditis and number of cycles of nivolumab was also tested. Results: Six of 18 patients developed hypothyroidism. The t test comparing the 2 groups demonstrated significant differences in SUVmean (P 5 0.04), SUVmax (P 5 0.04), and total lesion glycolysis (P 5 0.02) of the thyroid gland. Two of 4 patients who developed thyroiditis and had increased 18F-FDG uptake in the thyroid gland had a normal TSH level at the time of follow-up 18F-FDG PET/CT. Patients who developed thyroiditis with subsequent hypothyroidism stayed longer on therapy (10.6 cycles) than patients without thyroiditis (7.6 cycles), but the trend was not statistically significant. No significant difference in PET/CT parameters was observed for pituitary gland, liver, or spleen. Conclusion: 18F-FDG PET/CT can predict the development of thyroiditis with subsequent hypothyroidism before laboratory testing. Further study is required to confirm the positive trend between thyroiditis and duration of therapy.

AB - Our primary purpose was to determine whether increased 18FFDG uptake in the thyroid gland predicts development of thyroiditis with subsequent hypothyroidism in patients undergoing immunotherapy with nivolumab for lung cancer. Secondarily, we determined whether 18F-FDG uptake in the thyroid gland correlates with number of administered cycles of nivolumab. Methods: Retrospective chart review over 2 y found 18 lung cancer patients treated with nivolumab who underwent 18FFDG PET/CT before and during therapy. SUVmean, SUVmax, and total lesion glycolysis of the thyroid gland were measured. SUVs were also measured for the pituitary gland, liver, and spleen. Patients underwent monthly thyroid testing. PET/CT parameters were analyzed by unpaired t testing for differences between 2 groups (patients who developed hypothyroidism and those who did not). Correlation between development of thyroiditis and number of cycles of nivolumab was also tested. Results: Six of 18 patients developed hypothyroidism. The t test comparing the 2 groups demonstrated significant differences in SUVmean (P 5 0.04), SUVmax (P 5 0.04), and total lesion glycolysis (P 5 0.02) of the thyroid gland. Two of 4 patients who developed thyroiditis and had increased 18F-FDG uptake in the thyroid gland had a normal TSH level at the time of follow-up 18F-FDG PET/CT. Patients who developed thyroiditis with subsequent hypothyroidism stayed longer on therapy (10.6 cycles) than patients without thyroiditis (7.6 cycles), but the trend was not statistically significant. No significant difference in PET/CT parameters was observed for pituitary gland, liver, or spleen. Conclusion: 18F-FDG PET/CT can predict the development of thyroiditis with subsequent hypothyroidism before laboratory testing. Further study is required to confirm the positive trend between thyroiditis and duration of therapy.

KW - FFDG-PET/CT

KW - Immunotherapy

KW - Lung

KW - Lung cancer

KW - Molecular imaging

KW - Oncology

KW - PET/CT

KW - Thyroiditis

UR - http://www.scopus.com/inward/record.url?scp=85053390325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053390325&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 260

EP - 264

JO - Journal of Nuclear Medicine Technology

T2 - Journal of Nuclear Medicine Technology

JF - Journal of Nuclear Medicine Technology

SN - 0091-4916

IS - 3

ER -